Volume 26, Number 10—October 2020
Research
Sequential Acquisition of Human Papillomavirus Infection at Genital and Anal Sites, Liuzhou, China
Feixue Wei1, Yingying Su1, Xuelian Cui, Xiaojuan Yu, Yafei Li, Qiaoqiao Song, Kai Yin, Shoujie Huang, Mingqiang Li, Jun Zhang, Ting Wu
, and Ningshao Xia
, and Ningshao Xia
Table 1
Incidence rate of sequential HPV infection in the anus for participants with or without previous genital HPV infection of the same type by sex in Liuzhou, China, 2014–2016*
| HPV status at genital site before anal infection | Positive for HPV type at anal site |
||||||
|---|---|---|---|---|---|---|---|
| Men |
Women |
||||||
| No. | Incidence/1,000 person-months (95% CI) | HR (95% CI) | No. | Incidence/1,000 person-months (95% CI) | HR (95% CI) | ||
| Any HPV | |||||||
| Negative | 52 | 3.8 (2.9–4.9) | 1.0 | 149 | 6.2 (5.3–7.3) | 1.0 | |
| Positive |
14 |
8.8 (5.2–14.8) |
2.6 (1.4–4.6) |
87 |
25.9 (21.0–31.9) |
4.4 (3.4–5.8) |
|
| High-risk HPV | |||||||
| Negative | 33 | 2.4 (1.7–3.3) | 1.0 | 136 | 5.6 (4.8–6.7) | 1.0 | |
| Positive |
13 |
8.9 (5.2–15.4) |
4.2 (2.2–8.0) |
82 |
25.2 (20.3–31.3) |
4.7 (3.6–6.2) |
|
| 9V-HPV | |||||||
| Negative | 35 | 2.5 (1.8–3.5) | 1.0 | 69 | 2.8 (2.2–3.6) | 1.0 | |
| Positive |
5 |
6.0 (2.5–14.3) |
2.8 (1.1–6.9) |
32 |
19.8 (14.0–28.0) |
7.6 (5.0–11.5) |
|
| HPV 16/18 | |||||||
| Negative | 7 | 0.5 (0.2–1.1) | 1.0 | 20 | 0.8 (0.5–1.3) | 1.0 | |
| Positive |
1 |
3.7 (0.5–26.0) |
10.4 (1.3–85.9) |
11 |
16.9 (9.4–30.5) |
25.4 (12.0–53.6) |
|
| HPV 6/11 | |||||||
| Negative | 20 | 1.4 (0.9–2.2) | 1.0 | 13 | 0.5 (0.3–0.9) | 1.0 | |
| Positive | 1 | 5.4 (0.8–38.7) | 4.0 (0.5–30.5) | 3 | 15.6 (5.0–48.3) | 35.4 (9.9–126.9) | |
| HPV 6 | |||||||
| Negative | 10 | 0.7 (0.4–1.3) | 1.0 | 8 | 0.3 (0.2–0.7) | 1.0 | |
| Positive |
1 |
9.6 (1.4–68.2) |
11.9 (1.5–96.2) |
2 |
27.5 (6.9–110.1) |
95.2 (19.7–459.9) |
|
| HPV 11 | |||||||
| Negative | 11 | 0.8 (0.4–1.4) | NE | 5 | 0.2 (0.1–0.5) | 1.0 | |
| Positive |
0 |
0 |
NE |
1 |
7.8 (1.1–55.3) |
43.7 (5.1–375.1) |
|
| HPV 16 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 11 | 0.5 (0.3–0.8) | 1.0 | |
| Positive |
1 |
6.7 (0.9–47.5) |
52.4 (4.7–584.6) |
8 |
16.9 (8.5–33.9) |
45.8 (17.9–117.1) |
|
| HPV 18 | |||||||
| Negative | 5 | 0.4 (0.2–0.9) | NE | 9 | 0.4 (0.2–0.7) | 1.0 | |
| Positive |
0 |
0 |
NE |
3 |
13.5 (4.4–42.0) |
38.0 (10.3–140.6) |
|
| HPV 31 | |||||||
| Negative | 0 | 0 | NE | 2 | 0.1 (0.0–0.3) | 1.0 | |
| Positive |
0 |
0 |
NE |
3 |
22.1 (7.1–68.7) |
289.6 (48.2–1,740.9) |
|
| HPV 33 | |||||||
| Negative | 4 | 0.3 (0.1–0.8) | 1.0 | 12 | 0.5 (0.3–0.9) | 1.0 | |
| Positive |
1 |
12.4 (1.7–88.2) |
71.9 (7.4–700.0) |
5 |
30.0 (12.5–72.1) |
68.3 (23.9–194.9) |
|
| HPV 35 | |||||||
| Negative | 1 | 0.1 (0.0–0.5) | 1.0 | 3 | 0.1 (0.0–0.4) | 1.0 | |
| Positive |
1 |
19.0 (2.7–134.5) |
279.0 (17.2–4,524.7) |
2 |
13.1 (3.3–52.4) |
148.5 (20.8–1,058.9) |
|
| HPV 39 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 17 | 0.7 (0.4–1.2) | 1.0 | |
| Positive |
2 |
9.7 (2.4–38.8) |
57.4 (8.0–408.9) |
15 |
34.6 (20.9–57.4) |
46.0 (22.6–93.9) |
|
| HPV 45 | |||||||
| Negative | 1 | 0.1 (0.0–0.5) | 1.0 | 1 | 0.0 (0.0–0.3) | NE | |
| Positive |
1 |
36.5 (5.1–258.8) |
381.9 (23.9–6,105.8) |
0 |
0 |
NE |
|
| HPV 51 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 15 | 0.6 (0.4–1.0) | 1.0 | |
| Positive |
1 |
11.8 (1.7–83.6) |
84.0 (7.6–9,277.9) |
4 |
21.8 (8.2–58.1) |
40.9 (13.4–124.8) |
|
| HPV 52 | |||||||
| Negative | 8 | 0.6 (0.3–1.2) | 1.0 | 41 | 1.8 (1.3–2.5) | 1.0 | |
| Positive |
3 |
9.2 (3.0–28.4) |
15.9 (4.2–60.1) |
29 |
25.5 (17.7–36.7) |
14.7 (9.1–23.7) |
|
| HPV 56 | |||||||
| Negative | 2 | 0.1 (0.0–0.6) | 1.0 | 6 | 0.2 (0.1–0.6) | 1.0 | |
| Positive |
1 |
8.7 (1.2–61.9) |
127.6 (8.0–2,039.7) |
4 |
18.9 (7.1–50.3) |
160.2 (39.4–650.7) |
|
| HPV 58 | |||||||
| Negative | 5 | 0.4 (0.2–0.9) | 1.0 | 24 | 1.0 (0.7–1.5) | 1.0 | |
| Positive |
1 |
2.9 (0.4–20.9) |
8.6 (0.99–74.7) |
11 |
20.4 (11.3–36.9) |
20.7 (10.1–42.3) |
|
| HPV 59 | |||||||
| Negative | 3 | 0.2 (0.1–0.7) | 1.0 | 10 | 0.4 (0.2–0.8) | 1.0 | |
| Positive |
1 |
10.0 (1.4–71.3) |
48.5 (5.0–467.3) |
8 |
30.4 (15.2–60.8) |
69.8 (27.0–180.7) |
|
| HPV 66 | |||||||
| Negative | 0 | 0 | NE | 5 | 0.2 (0.1–0.5) | 1.0 | |
| Positive |
0 |
0 |
NE |
2 |
18.2 (4.5–72.7) |
83.3 (16.1–430.0) |
|
| HPV 68 | |||||||
| Negative | 0 | 0 | NE | 0 | 0 | NE | |
| Positive | 0 | NE | NE | 0 | NE | NE | |
*HRs and 95% CIs of sequential grouped HPV infection were calculated based on individual results. 9V-HPV, 9-valent vaccine-related HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58); HR-HPV, high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68); HPV, human papillomavirus; HR, hazard ratio; NE, not estimable..
1These authors contributed equally to this article.
Page created: June 21, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.